The tweet was deleted by the author.
But we saved everything 🙂.
Taysha Gene Therapies, Inc. will disclose its financial results for the second quarter of 2026 and provide a corporate update next week.
The company has invited stakeholders to access additional information via its official website. This upcoming announcement is anticipated to give investors and analysts a clearer picture of the firm’s financial health and strategic direction. Details are being clarified.
View post on X Loading...
Earlier this year, Taysha Gene Therapies secured a commercial supply agreement with Catalent for TSHA-102 as reported in a recent company update. The company’s stock traded at $5.86 after news of the Catalent partnership, according to market data published this month. These developments come ahead of the upcoming financial disclosure.